Retifanlimab

No information is available on the clinical use of retifanlimab during breastfeeding. Because retifanlimab is a large protein molecule with a molecular weight of 148,000 Da, the amount in milk is likely to be very low. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal. Waiting for at least 2 weeks postpartum to resume therapy may minimize transfer to the infant.[1] The manufacturer recommends avoiding breastfeeding during therapy and for 4 months after the last dose.